Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MELK | Q14680 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.37 |
| ▸ | RAB9A | P51151 | 5/20 | 0.37 |
| ▸ | NPC1 | O15118 | 4/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | RET | P07949 | 4/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | FYN | P06241 | 1/20 | 0.33 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.33 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.33 |
| ▸ | CSGALNACT1 | Q8TDX6 | 4/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3824983 | 0.92 | MAPT (0.41) | MELKSMN1; SMN2RAB9ANPC1LMNA | |
| SCHEMBL4484744 | 0.89 | NPC1 (0.43) | MELKSMN1; SMN2RAB9ANPC1LMNA | |
| SCHEMBL13711814 | 0.88 | MELK (0.40) | MELKSMN1; SMN2RAB9ANPC1LMNA | |
| SCHEMBL3851392 | 0.86 | SMN1; SMN2 (0.39) | SMN1; SMN2RAB9ANPC1LMNAPOLB | |
| SCHEMBL3824968 | 0.85 | MELK (0.46) | MELKKMT2AMAPTALDH1A1KDM4E | |
| SCHEMBL3818041 | 0.80 | KDM4E (0.37) | MELKRAB9ANPC1LMNAKMT2A | |
| SCHEMBL4464972 | 0.79 | MELK (0.42) | MELKSMN1; SMN2RAB9ANPC1LMNA | |
| SCHEMBL4468601 | 0.77 | MELK (0.48) | MELKPOLBKMT2AMAPTALDH1A1 | |
| SCHEMBL4466525 | 0.77 | MELK (0.43) | MELKSMN1; SMN2RAB9ANPC1LMNA | |
| SCHEMBL4469876 | 0.76 | MELK (0.45) | MELKRAB9ANPC1LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8470821-B2 | PDE4B inhibitors and uses therefor | PLEXXIKON INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-8470821-B2 | PDE4B inhibitors and uses therefor | PLEXXIKON INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-8470821-B2 | PDE4B inhibitors and uses therefor | PLEXXIKON INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20090286793-A1 | PDE4B INHIBITORS AND USES THEREFOR | PLEXXIKON, INC. | 2009-11-19 | — | — | US | disclosed |
| US-20090286793-A1 | PDE4B INHIBITORS AND USES THEREFOR | PLEXXIKON, INC. | 2009-11-19 | — | — | US | disclosed |
| US-20090286793-A1 | PDE4B INHIBITORS AND USES THEREFOR | PLEXXIKON, INC. | 2009-11-19 | — | — | US | disclosed |
| US-7585859-B2 | PDE4B inhibitors and uses therefor | PLEXXIKON, INC. (US) | 2009-09-08 | — | — | US | disclosed |
| US-7585859-B2 | PDE4B inhibitors and uses therefor | PLEXXIKON, INC. (US) | 2009-09-08 | — | — | US | disclosed |
| US-7585859-B2 | PDE4B inhibitors and uses therefor | PLEXXIKON, INC. (US) | 2009-09-08 | — | — | US | disclosed |
| EP-1742627-A4 | PDE4B INHIBITORS AND USES THEREFOR | PLEXXIKON INC (US) | 2009-08-26 | — | — | EP | disclosed |
| EP-1742627-A2 | PDE4B INHIBITORS AND USES THEREFOR | PLEXXIKON, INC. (US) | 2007-01-17 | — | — | EP | disclosed |
| WO-2006078287-A9 | PDE4B INHIBITORS AND USES THEREFOR | PLEXXIKON INC (US) | 2006-08-31 | — | — | WO | disclosed |
| WO-2006078287-A2 | PDE4B INHIBITORS AND USES THEREFOR | PLEXXIKON, INC. (US) | 2006-07-27 | — | — | WO | disclosed |
| US-20060041006-A1 | PDE4B inhibitors and uses therefor | PLEXXIKON, INC. | 2006-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286793-A1 | PDE4B INHIBITORS AND USES THEREFOR | PDE4B, PDE7B, PDE4A | MELK 3735/4885SMN1; SMN2 1379/4885RAB9A 1343/4885 |
| US-20060041006-A1 | PDE4B inhibitors and uses therefor | PDE4B, PDE7B, PDE4A | MELK 3735/4885SMN1; SMN2 1379/4885RAB9A 1343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.